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Highlights:
Sinonasal mucosal melanoma is defined as a rare and highly aggressive tumour, often carrying a 
poor prognosis because of local invasion and early distant metastasis.
Sinonasal mucosal melanoma needs to be considered in the differential diagnosis of sinonasal 
malignancies.
In our case report, a one-time reconstruction treatment and endoscopic approach are described.
One-time reconstruction shortened patient’s hospitalization, improved patient’s quality of life, if not 
survival, and allowed him to benefit immunotherapic treatment as soon as possible after tumour’s 
surgical resection
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Abstract:
Sinonasal mucosal melanoma is a rare and highly aggressive tumour. This tumour often carries a 
poor prognosis because of local invasion and early distant metastasis. It’s, in fact, an aggressive, 
fortunately rare, disease. It’s more common among population in their seventies, with a prolonged 
course due to innocuous symptoms. We report a case of sinonasal mucosal melanoma in a 56-years 
old male who presented with a brownish sinonasal mass involving right nasal fossa, swelling and 
spontaneous epistaxis. We report this case for the one-time reconstruction treatment performed by 
our team.
Introduction:
Sinonasal mucosal melanoma are rare tumours that need to be considered in the differential 
diagnosis of sinonasal malignancies, like carcinoma, lymphoma, sarcoma and olfactory 
neuroblastoma. Incidence is 0.2–1 per million[1,2] with a poor prognosis of 5-years overall survival 
rate, ranging between 20-43%[3,4] that can be attributed to various factors: delayed diagnosis due to 
asymptomatic early stages; non-specific presenting complaint; lack of overt visibility; later stage 
presentation with locally advanced disease; aggressive nature of the disease, showed by local 
recurrence, cervical lymphadenopathy and distant metastases, making it difficult to identify the 
beast treatment; proximity to vital neurovascular structures, which makes radical surgery rarely 
feasible due to close relation with important vascular and nervous structures[5-7]. All these factors 
make surgical management of sinonasal cancer challenging, without considering the multiple 
histopathological types of tumours found, and above all, late diagnosis[8,9]. This tumour is poorly 
radiosensitive, and surgical resection is preferred for localized disease. Advanced age, tumour size, 
nodal status, and distant metastasis status, have been identified as independent predictors of poorer 
survival.
Case report: 
A 56-years old male presented on August 2016 to our Department of Maxillofacial Surgery for 
evaluation of a 3x2 cm nasal swelling without erythema, nasal obstruction and epistaxis since June 
2016. The patient didn’t lament cranial nerves dysfunction. CT scan showed a 55x15mm 
neoformation in the right nasal fossa, extending to the tail of the medium inferior turbinate, to the 
nose bridge skin and to some right ethmoidal cells. Biopsy  resulted in a right nasal fossa 
melanoma. Tumour was then staged as T4a for the ethmoidonasal localization, maxillary sinus 
mucosal invasion, and nose bridge skin involvement. The patient, after a surgical plan agreed 
between Maxillofacial, Neurosurgical, Pathologic, Oncologic and Radiotherapic teams, was then 
surgically treated with a one-time reconstruction consisting in a frontal rotation flap over right 
supraorbital artery. After performing an endoscopically assisted removal of the mass and bilateral 
Draf 3-ethmoidectomy, a right medial maxillectomy, the removal of the septum, a whole-thickness 
4x4 removal of the external skin of the nasal pyramid and a peripheral frozen section exam, 
reconstruction by frontal flap was performed. The Neurosurgical team contributed to the treatment, 
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performing the reconstruction of the anterior cranial base with dural membrane and double-layer 
fibrin glue.
Intraoperative frozen section analysis performed by the Pathologists resulted in an invasive 
melanoma with mitotic index >1mm2  (hotspot to 6 mitotis/ mm2), tumoral necrosis and 
osteocartilaginous tissue involvement, involving perichondrium of right nasal pyramid, with focal 
infiltration of  bone tissue of nasal dorsum. 
The Oncology consultant prescribed esophagogastroduodenoscopy, colonscopy and total-body PET, 
that showed multiple lymphoadenopathies in the celiac area, at the hepatic hilum and in the 
mesenteric fat tissue without pathological captation of the tracer. The patient was finally discharged 
after a 25-days hospitalization, after the endoscopical treatment of a left liquoral fistula, with 
Neurosurgical team’s contrbution, and negative  esophagogastroduodenoscopy and colonscopy, 
prescribed by the Oncologist. PET-CT scan showed no pathological captation of the tracer. Our 
patient is currently being treated with Ipilimumab 3mg/kg every 3 weeks. 
Discussion:
In literature[4], sinonasal melanoma is mostly T3 e T4, and in our case we defined it a T4a for 
cartilage, bone and overlying skin involvement. As no lymph nodes were involved, and no 
metastases were found, we defined it a T4A N0 M0 (Stage IV A)
A general consensus has been reached to consider surgery as a first-line treatment [6,18,19] and, as 
might be expected, it is demonstrated that patients who did not have surgery had a poorer 
outcome[10]. The tumour must be widely resected with 1,5-2 cm negative surgical margins (≥5 mm 
on definitive histological examination of the operative specimen).  Failure to achieve local control 
is associated with an increased risk of distant disease and leads to significantly decreased overall 
survival. However, more than 50% of patients will develop distant metastases despite having good 
local tumour control[11].
In our experience, endoscopic approach was preferred for melanoma’s localization, our team’s 
experience and the collaboration with the Neurosurgery team. The one-time reconstruction was 
added to grant a shorter hospitalization, and a quicker discharge of the patient to allow him to start 
his immunotherapeutic treatment, and to improve patient’s quality of life, if not survival, by 
reconstructing as soon as possible his aesthetic features. Our patient isn’t undergoing radiotherapy 
as external beam radiotherapy has a questionable survival benefit[12] as patients tend to do poorly 
regardless of adjuvant radiation status. Given the added morbidity of radiation to the nasal cavity 
and the skull base and the lack of data supporting a survival benefit, patients may best be served by 
undergoing aggressive surgical resection and close monitoring or palliative resection, in cases 
where negative margins cannot be reached. [13] Endoscopic procedure’s major postoperative 
complications include cerebrospinal fluid leak. Minor complications include fever. As previously 
described, we observed liquoral fistula complication in our case. Overall, complications were 
observed in 10.3% of the patients in Lombardi’s et al. work[14] 
Elective neck dissection (END) is not usually performed in Patients with sinonasal disease, 
although the incidence of nodal disease is higher in patients with oral cavity mucosal melanoma[6, 15] 
The majority of studies have recommended a conservative approach to neck management is needed 
but some have suggested routine conservative END, often to include levels I-V.[15] 
The role of chemotherapy in the management of mucosal melanoma is considered to be limited. 
Under most circumstances, it is considered to be palliative at best. There is some evidence to 
suggest prolonged survival with the addition of chemotherapy. Therapy may include dacarbazine, 
platinum analogues, nitrosureas, and microtubular toxins.[16] Our patient is currently being treated 
with Ipilimumab 3mg/kg every 3 weeks. Although monoclonal antibodies targeting immune 
checkpoint proteins (include Ipilimumab and PD-1/PD-L1 antibodies) have elicited long-lasting 
anti-cancer response in metastatic melanoma, randomized clinical trials on checkpoint inhibitors in 
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patients with metastatic MM are limited. It is expected that the role of checkpoint inhibitors in 
patients with metastatic MM will be further clarified after results of more prospective studies are 
ultimately available in future. In case of metastazation considered inoperable targeted therapies and 
immunotherapies with checkpoint inhibitors can be considered. PD-1 inhibitors or their 
combination with ipilimumab appear to show the highest response rates and longest progression-
free survival. In case of a KIT mutation, additional analysis of NRAS is recommended before 
treating with a KIT-inhibitor. In the rare event of a BRAF V600 mutation, targeted therapy 
analogous to cutaneous melanomas is recommended. [20]
Conclusion: 
Sinonasal melanoma is an aggressive disease, best treated with primary tumour resection. In our 
experience, treating our patient with a one-time reconstruction, given the extent of the tumour 
resected, shortened his hospitalization, allowing him to benefit the immunotherapeutic treatment as 
soon as possible after tumour’s surgical resection, that is considered as a first-line treatment. One-
time reconstruction improved, by reconstructing his aesthetic features, patient’s quality of life, if not 
survival.
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      Figure 1 – A,b,c) Removal of the septum d) Frontal flap e) 1 month later
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      Figure 2 – CT scans before (a) and after surgery (b) Draf III procedure involves removal of the inferior portion of the interfrontal 
septum, the superior part of the nasal septum, and the frontal sinus floor to the orbit laterally. The lamina papyracea and posterior 
walls of the frontal sinus remain intact. Postoperatively, a wide opening into both frontal sinuses can be seen. The surgical defect in 
the superior nasal septum should not be mistaken for an unintended postoperative septal perforation.
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     Figure 3 – Before (a,c) and after surgery (b,d)
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Table 1.
American Joint Committee on cancer staging mucosal melanoma of the head and the neck, 7th 
edition. 
Primary tumour (T)
TX     Primary tumour cannot be assessed
T3     Mucosal disease
T4a     Moderately advanced disease : tumour involving deep soft tissue, cartilage, bone, or        overlying skin 
T4b
    Very advanced disease : tumour involving brain, dura, skull base, lower cranial   
     nerves (IX, X, XI, XII), masticator space, carotid artery, prevertebral space, or   
     mediastinal       structures 
Regional lymph nodes (N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastases
N1 Regional lymph node metastases present
Distant metastasis (M)
M0 No distant metastasis
M1 Distant metastasis present
Staging
Stage III T3, N0, M0
T4a, N0, M0Stage IV A T3-T4a, N1, M0
Stage IV B T4b, any N, M0
Stage IV C Any T, any N, M1
